# US 2025/0154174 A1 · Bicyclic heterocycles as mrgprx2 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154174 A1
- Document ID: US20250154174A1
- Status: Published application
- Kind: A1
- Application number: 18/941,025
- Filed: 2024-11-08
- Published: 2025-05-15
- Earliest claimed: 2023-11-10
- Applicants: Incyte Corporation
- Inventors: Minh Nguyen; Hai Fen Ye
- Web page: https://patentgrep.com/patent/US20250154174A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to bicyclic heterocycles of Formula (I), and pharmaceutical compositions of the same, that are modulators, antagonists, or inhibitors of the G protein-coupled receptor MRGPRX2 and are useful in the treatment of MRGPRX2 dependent conditions such as inflammatory diseases.

## Claims

### Claim 1

A compound having Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X1 is N or CR1;
X3 is N or CR3;
X4 is N or CR4;
X5 is N or CR5;
X6 is N or CR6;
R1, R2, R3, R4, R5, and R6 are each independently selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, NO2, ORa1SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming R1, R2, R3, R4, R5, and R6 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10A; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R1, R2, R3, R4, R5, and R6 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B;
A is a group of the Formula (A-1) or (A-2):
wherein represents the point of attachment of A to the remainder of the molecule;
Cy is a ring selected from 5-10 membered heteroaryl and 5-10 membered heterocycloalkyl; and wherein the 5-10 membered heteroaryl and 5-10 membered heterocycloalkyl forming Cy are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy;
each RCy is independently selected from D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming RCy are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming RCy are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy2;
each RCy1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and RCy2; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming RCy1 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy2;
each RCy2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming RCy2 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
R7 is selected from D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4; wherein the C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming R7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R20A; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R20B;
n is an integer from 0 to 8;
each R10A is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and R10B; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R10A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10B;
each R10B is independently selected from C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, NO2, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)ORa5, NRc5C(O)NRc5Rd5, C(═NRe5)Rb5, C(═NORa5)Rb5, C(═NRe5)NRc5Rd5, NRc5C(═NRe5)NRc5Rd5, NRc5S(O)Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, and S(O)2NRc5Rd5; wherein the C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-12 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming R10B are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;
each R11 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming R11 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R11 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg2;
each R20A is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R20A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R20B;
each R20B is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)ORa7, NRc7S(O)Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, and S(O)2NRc7Rd7; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene forming R20B are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra3, Rc3, Rd3, Ra4, Rc4, Rd4, Ra5, Rc5, Rd5, Ra6, Rc6, Rd6, Ra7, Rc7, and Rd7 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl forming Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra3, Rc3, Rd3, Ra4, Rc4, Rd4, Ra5, Rc5, Rd5, Ra6, Rc6, Rd6, Ra7, Rc7, and Rd7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra3, Rc3, Rd3, Ra4, Rc4, Rd4, Ra5, Rc5, Rd5, Ra6, Rc6, Rd6, Ra7, Rc7, and Rd7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg2;
or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc5 and Rd5 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc6 and Rd6 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc7 and Rd7 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Rb1, Rb2, Rb3, Rb4, Rb5, Rb6, and Rb7 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl forming Rb1, Rb2, Rb3, Rb4, Rb5, Rb6, and Rb7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming Rb1, Rb2, Rb3, Rb4, Rb5, Rb6, and Rb7 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg2;
each Re1, Re2, Re4, and Re5 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl and di(C1-6 alkyl)aminosulfonyl;
each Rg1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg2;
each Rg2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, CN, ORa8, SRa8, C(O)Rb8, C(O)NRc8Rd8, C(O)ORa8, NRc8Rd8, NRc8C(O)Rb8, NRc8C(O)ORa8, NRc8S(O)Rb8, NRc8S(O)2Rb8, NRc8S(O)2NRc8Rd8, S(O)Rb8, S(O)NRc8Rd8, S(O)2Rb8, and S(O)2NRc8Rd8; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl forming Rg2 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh1;
each Ra8, Rc8, and Rd8 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl forming Ra8, Rc8, and Rd8 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming Ra8, Rc8, and Rd8 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh2;
each Rb8 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein the C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl forming Rb8 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh1; and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming Rb11 are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh2;
each Rh1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rh2;
each Rh2 is independently selected from D, OH, NO2, CN, halo, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-2 alkylene, C1-6 alkoxy, C1-6 haloalkoxy, C1-3 alkoxy-C1-3 alkyl, C1-3 alkoxy-C1-3 alkoxy, HO—C1-3 alkoxy, HO—C1-3 alkyl, cyano-C1-3 alkyl, H2N—C1-3 alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino;
wherein at each occurrence, a heterocycloalkyl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heterocycloalkyl group are optionally oxidized; and a ring-forming carbon atom of the heterocycloalkyl group is optionally substituted by oxo to form a carbonyl group; and
at each occurrence, a heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heteroaryl group are optionally oxidized; and a ring-forming carbon atom of the heteroaryl group is optionally substituted by oxo to form a carbonyl group;
with the proviso that the compound is not one of the following compounds:
N1-(5-Methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-N4-2-pyridinyl-1,4-cyclohexanediamine;
N1,N4-Bis(5,6-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-1,4-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N4-(tetrahydro-2H-pyran-4-yl)-1,4-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-(tetrahydro-2H-pyran-4-yl)-1,3-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-[1-(phenylmethyl)-4-piperidinyl]-1,3-cyclohexanediamine.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has Formula (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F):
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and A are as defined in claim 1.

### Claim 3 (depends on 1, 2)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is other than a compound of Formula (II-A); the compound is other than a compound of Formula (II-B); the compound is other than a compound of Formula (II-C); the compound is other than a compound of Formula (II-D); the compound is other than a compound of Formula (II-E); and/or the compound is other than a compound of Formula (II-F); wherein Formulae (II-A), (II-B), (II-C), (II-D), (II-E), and (II-F) are as defined in claim 2.

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-1).

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-3):

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-4), (A-5), (A-6), or (A-7):
wherein the bold and dashed lines in the Formulae (A-4), (A-5), (A-6), and (A-7) indicate relative (i.e., cis or trans) stereochemistry.

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-2).

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-8):

### Claim 9 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-9) or (A-10):
wherein the bold and dashed lines in the Formulae (A-7) and (A-8) indicate relative (i.e., cis or trans) stereochemistry.

### Claim 10 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-11), (A-12), (A-13) or (A-14):
wherein the wedged lines in the Formulae (A-11), (A-12), (A-13) and (A-14) indicate absolute (i.e., (R) or (S)) stereochemistry.

### Claim 11 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-15) or (A-16):
wherein the bold and dashed lines in the Formulae (A-15) and (A-16) indicate relative (i.e., cis or trans) stereochemistry.

### Claim 12 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein A is a group of the Formula (A-17), (A-18), (A-19) or (A-20):
wherein the wedged lines in the Formulae (A-17), (A-18), (A-19) and (A-20) indicate absolute (i.e., (R) or (S)) stereochemistry.

### Claim 13 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X1 is CR1.

### Claim 14 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X1 is N.

### Claim 15 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R1 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R2 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 16 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R1 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa1; wherein the C1-6 alkyl forming R1 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 17 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R1 is selected from H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 18 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R1 is H.

### Claim 19 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X2 is CR2.

### Claim 20 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X2 is N.

### Claim 21 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R2 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R2 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 22 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R2 is H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 23 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R2 is C1-6 alkyl, C1-6 haloalkyl, or halo.

### Claim 24 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R2 is CF3, CH3, or Br.

### Claim 25 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X3 is CR3.

### Claim 26 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X3 is N.

### Claim 27 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R3 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R3 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 28 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R3 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa1; wherein the C1-6 alkyl forming R3 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 29 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R3 is H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 30 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R3 is H.

### Claim 31 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X4 is CR4.

### Claim 32 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X4 is N.

### Claim 33 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R4 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R4 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 34 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R4 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa1; wherein the C1-6 alkyl forming R4 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 35 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R4 is H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 36 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R4 is H.

### Claim 37 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X5 is CR5.

### Claim 38 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X5 is N.

### Claim 39 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R5 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R5 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 40 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R5 is H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 41 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R5 is H or C1-6 haloalkyl.

### Claim 42 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R5 is CF3.

### Claim 43 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R5 is H.

### Claim 44 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X6 is CR6.

### Claim 45 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X6 is N.

### Claim 46 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R6 is selected from H, D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)(═NH)Rb1, S(O)2NRc1Rd1, P(O)(NH2)Rb1, or P(O)(NH2)ORa1; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R6 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 47 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R6 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa1; wherein the C1-6 alkyl forming R6 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R10B.

### Claim 48 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R6 is H, D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 49 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R6 is H.

### Claim 50 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R7 is selected from D, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming R7 are each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from R20B.

### Claim 51 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein R7 is D, C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), CN, or halo (such as F, Cl, or Br).

### Claim 52 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from RCy.

### Claim 53 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

### Claim 54 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy.

### Claim 55 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1, 2, or 3 substituents independently selected from RCy.

### Claim 56 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1 or 2 substituents independently selected from RCy.

### Claim 57 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is optionally substituted with 1 substituent selected from RCy.

### Claim 58 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is unsubstituted.

### Claim 59 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from RCy.

### Claim 60 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

### Claim 61 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy.

### Claim 62 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from RCy.

### Claim 63 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from RCy.

### Claim 64 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is 5-10 membered heteroaryl optionally substituted with 1 substituent selected from RCy.

### Claim 65 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is unsubstituted 5-10 membered heteroaryl.

### Claim 66 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Cy is unsubstituted or substituted 3H-imidazo[4,5-c]pyridinyl, 1,6-naphthyridinyl, imidazo[1,5-a]pyrazinyl, pyrazolo[1,5-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyridinyl, or imidazo[1,2-c]pyrimidinyl.

### Claim 67 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein each RCy is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NR2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl forming RCy are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy2.

### Claim 68 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein each RCy is selected from C1-6 alkyl (such as methyl or ethyl), C1-6 haloalkyl (such as CF3, CHF2, CF2CF3), halo (such as F, Cl, or Br), and ORa2 (such as methoxy or ethoxy).

### Claim 69 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein each RCy is selected from C1-6 alkyl.

### Claim 70 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein RCy is CH3.

### Claim 71 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein n is 0.

### Claim 72 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein n is an integer from 1 to 4.

### Claim 73 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein n is 1.

### Claim 74 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein:
X1 is N or CR1;
X3 is N or CR3;
X4 is N or CR4;
X5 is N or CR5;
X6 is N or CR6;
R1, R2, R3, R4, R5, and R6 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, NRc1Rd1, and S(O)2Rb1;
A is a group of the Formula (A-1) or (A-2):
wherein represents the point of attachment of A to the remainder of the molecule;
Cy is a ring selected from 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy;
each RCy is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
R7 is selected from D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NR4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4;
n is an integer from 0 to 8;
each Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Rb1, Rb2, and Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Re2 and Re4 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl and di(C1-6 alkyl)aminosulfonyl;
each Rg1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg2;
each Rg2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, CN, ORa8, SRa8, C(O)Rb8, C(O)NRc8Rd8, C(O)ORa8, NRc8Rd8, NRc8C(O)Rb8, NRc8C(O)ORa8, NRc8S(O)Rb8, NRc8S(O)2Rb8, NRc8S(O)2NRc8Rd8, S(O)Rb8, S(O)NRc8Rd8, S(O)2Rb8, and S(O)2NRc8Rd8;
each Ra8, Rc8, and Rd8 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Rb8 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
wherein at each occurrence, a heterocycloalkyl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heterocycloalkyl group are optionally oxidized; and a ring-forming carbon atom of the heterocycloalkyl group is optionally substituted by oxo to form a carbonyl group; and
at each occurrence, a heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heteroaryl group are optionally oxidized; and a ring-forming carbon atom of the heteroaryl group is optionally substituted by oxo to form a carbonyl group;
with the proviso that the compound is not one of the following compounds:
N1-(5-Methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-N4-2-pyridinyl-1,4-cyclohexanediamine;
N1,N4-Bis(5,6-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-1,4-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N4-(tetrahydro-2H-pyran-4-yl)-1,4-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-(tetrahydro-2H-pyran-4-yl)-1,3-cyclohexanediamine;
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-[1-(phenylmethyl)-4-piperidinyl]-1,3-cyclohexanediamine.

### Claim 75 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has Formula (IIA):
wherein:
R1, R2, R4, R5, and R6 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, NRc1Rd1, and S(O)2Rb1;
A is a group of the Formula (A-4):
wherein represents the point of attachment of A to the remainder of the molecule;
Cy is a ring selected from 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy;
each RCy is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
R7 is selected from D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4;
n is an integer from 0 to 8;
each Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Rb1, Rb2, and Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Re2 and Re4 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl and di(C1-6 alkyl)aminosulfonyl;
each Rg1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg2;
each Rg2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, CN, ORa8, SRa8, C(O)Rb8, C(O)NRc8Rd8, C(O)ORa8, NRc8Rd8, NRc8C(O)Rb8, NRc8C(O)ORa8, NRc8S(O)Rb8, NRc8S(O)2Rb8, NRc8S(O)2NRc8Rd8, S(O)Rb8, S(O)NRc8Rd8, S(O)2Rb8, and S(O)2NRc8Rd8;
each Ra8, Rc8, and Rd8 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Rb8 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
wherein at each occurrence, a heterocycloalkyl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heterocycloalkyl group are optionally oxidized; and a ring-forming carbon atom of the heterocycloalkyl group is optionally substituted by oxo to form a carbonyl group; and
at each occurrence, a heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heteroaryl group are optionally oxidized; and a ring-forming carbon atom of the heteroaryl group is optionally substituted by oxo to form a carbonyl group.

### Claim 76 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has Formula (II-A):
wherein:
R1, R2, R4, R5, and R6 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, NRc1Rd1, and S(O)2Rb1;
A is a group of the Formula (A-9):
wherein represents the point of attachment of A to the remainder of the molecule;
Cy is a ring selected from 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy;
each RCy is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
R7 is selected from D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4;
n is an integer from 0 to 8;
each Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Rb1, Rb2, and Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Re2 and Re4 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl and di(C1-6 alkyl)aminosulfonyl;
each Rg1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg2;
each Rg2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, CN, ORa8, SRa8, C(O)Rb8, C(O)NRc8Rd8, C(O)ORa8, NRc8Rd8, NRc8C(O)Rb8, NRc8C(O)ORa8, NRc8S(O)Rb8, NRc8S(O)2Rb8, NRc8S(O)2NRc8Rd8, S(O)Rb8, S(O)NRc8Rd8, S(O)2Rb8, and S(O)2NRc8Rd8;
each Ra8, Rc8, and Rd8 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Rb8 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
wherein at each occurrence, a heterocycloalkyl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heterocycloalkyl group are optionally oxidized; and a ring-forming carbon atom of the heterocycloalkyl group is optionally substituted by oxo to form a carbonyl group; and
at each occurrence, a heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heteroaryl group are optionally oxidized; and a ring-forming carbon atom of the heteroaryl group is optionally substituted by oxo to form a carbonyl group.

### Claim 77 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has Formula (II-D):
wherein:
R2, R3, R5, and R6 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, NRc1Rd1, and S(O)2Rb1;
A is a group of the Formula (A-9):
wherein represents the point of attachment of A to the remainder of the molecule;
Cy is a ring selected from 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy;
each RCy is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-12 membered heterocycloalkyl, halo, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
R7 is selected from D, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRe4)Rb4, C(═NORa4)Rb4, C(═NRe4)NRc4Rd4, NRc4C(═NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4;
n is an integer from 0 to 8;
each Ra1, Rc1, Rd1, Ra2, Rc2, Rd2, Ra4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg1;
each Rb1, Rb2, and Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Re2 and Re4 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl and di(C1-6 alkyl)aminosulfonyl;
each Rg1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Rg2, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg2;
each Rg2 is independently selected from C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, CN, ORa8, SRa8, C(O)Rb8, C(O)NRc8Rd8, C(O)ORa8, NRc8Rd8, NRc8C(O)Rb8, NRc8C(O)ORa8, NRc8S(O)Rb8, NRc8S(O)2Rb8, NRc8S(O)2NRc8Rd8, S(O)Rb8, S(O)NRc8Rd8, S(O)2Rb8, and S(O)2NRc8Rd8;
each Ra8, Rc8, and Rd8 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
each Rb8 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl;
wherein at each occurrence, a heterocycloalkyl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heterocycloalkyl group are optionally oxidized; and a ring-forming carbon atom of the heterocycloalkyl group is optionally substituted by oxo to form a carbonyl group; and
at each occurrence, a heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; the N and S ring-forming heteroatoms of the heteroaryl group are optionally oxidized; and a ring-forming carbon atom of the heteroaryl group is optionally substituted by oxo to form a carbonyl group;
with the proviso that the compound is not one of the following compounds:
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-(tetrahydro-2H-pyran-4-yl)-1,3-cyclohexanediamine; and
N1-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N3-[1-(phenylmethyl)-4-piperidinyl]-1,3-cyclohexanediamine.

### Claim 78 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is selected from the following:
(1R,3S)—N1-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)-N3-(2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)cyclohexane-1,3-diamine;
(1s,4s)-N1-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)-N4-(2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)cyclohexane-1,4-diamine;
(1R,3S)—N1-(1,6-naphthyridin-5-yl)-N3-(2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)cyclohexane-1,3-diamine;
(1R,3S)—N1-(imidazo[1,5-a]pyrazin-8-yl)-N3-(2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)cyclohexane-1,3-diamine;
(1s,4s)-N1-(imidazo[1,5-a]pyrazin-8-yl)-N4-(2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)cyclohexane-1,4-diamine;
(1R,3S)—N1-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)-N3-(2-methyl-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-methyl-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(1,6-naphthyridin-5-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(1,6-naphthyridin-5-yl)cyclohexane-1,3-diamine;
(1R,3S)—N1—([1,2,4]triazolo[4,3-a]pyridin-3-yl)-N3-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2,5-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(1,6-naphthyridin-5-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(imidazo[1,5-a]pyrazin-8-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2,5-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(imidazo[1,5-a]pyrazin-8-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2,5-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(3-methyl-3H-imidazo[4,5-c]pyridin-4-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2-bromo-5-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(imidazo[1,2-c]pyrimidin-5-yl)cyclohexane-1,3-diamine;
(1S,3R)—N1-(2,5-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)-N3-(imidazo[1,2-c]pyrimidin-5-yl)cyclohexane-1,3-diamine; and
(1R,3S)—N1—([1,2,4]triazolo[4,3-a]pyridin-3-yl)-N3-(2,5-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclohexane-1,3-diamine.

### Claim 79 (depends on 1)

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 80 (depends on 1)

A method of treating an MRGPRX2 dependent condition in a patient comprising administering to the patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof of claim 1.

### Claim 81 (depends on 80)

The method of claim 80, wherein the MRGPRX2 dependent condition is an itch associated condition, a pain associated condition, a pseudo-allergic reaction, an autoimmune or inflammatory disorder, or a cancer or tumor associated condition.

### Claim 82 (depends on 81)

The method of claim 81, wherein the MRGPRX2 dependent condition is an itch associated condition.

### Claim 83 (depends on 82)

The method of claim 82, wherein the MRGPRX2 dependent condition is an itch associated condition selected from the group consisting of chronic itch; senile itch; contact dermatitis; allergic blepharitis; anaphylaxis; anaphylactoid drug reactions; anaphylactic shock; anemia; atopic dermatitis; bullous pemphigoid; candidiasis; chicken pox; end-stage renal failure; hemodialysis; cholestatic pruritus; chronic spontaneous urticaria; chronic inducible urticaria; contact dermatitis, dermatitis herpetiformis; diabetes; drug allergy, dry skin; dyshidrotic dermatitis; ectopic eczema; eosinophilic fasciitis; epidermolysis bullosa; erythrasma; food allergy; folliculitis; fungal skin infection; hemorrhoids; herpes; HIV infection; hodgkin's disease; hyperthyroidism; iodinated contrast dye allergy; iron deficiency anemia; kidney disease; leukemia, porphyrias; lymphoma; mast cell activation syndrome, malignancy; mastocystosis; multiple myeloma; neurodermatitis; onchocerciasis; Paget's disease; pediculosis; polycythemia rubra vera; prurigo nodularis; lichen planus; lichen sclerosis; pruritus ani; pseudo-allergic reactions; pseudorabies; psoriasis; rectal prolapse; sarcoidosis granulomas; scabies; schistosomiasis; scleroderma, severe stress, stasia dermatitis; swimmer's itch; thyroid disease; tinea cruris; uremic pruritus; rosacea; cutaneous amyloidosis; scleroderma; acne; wound healing; burn healing; ocular itch; and urticaria.

### Claim 84 (depends on 81)

The method of claim 81, wherein the MRGPRX2 dependent condition is a pain associated condition.

### Claim 85 (depends on 84)

The method of claim 84, wherein the MRGPRX2 dependent condition is a pain associated condition selected from the group consisting of acute pain, advanced prostate cancer, AIDS-related pain, ankylosing spondylitis, arachnoiditis, arthritis, arthrofibrosis, ataxic cerebral palsy, autoimmune atrophic gastritis, avascular necrosis, back pain, Behcet's disease (syndrome), burning mouth syndrome, bursitis, cancer pain, carpal tunnel, cauda equina syndrome, central pain syndrome, cerebral palsy, cervical stenosis, Charcot-Marie-Tooth (CMT) disease, chronic fatigue syndrome (CFS), chronic functional abdominal pain (CFAP), chronic pain, chronic pancreatitis, chronic pelvic pain syndrome, collapsed lung (pneumothorax), complex regional pain syndrome (CRPS), reflex sympathetic dystrophy syndrome (RDS), corneal neuropathic pain, Crohn's disease, degenerative disc disease, dental pain, Dercum's disease, dermatomyositis, diabetic peripheral neuropathy (DPN), dystonia, Ehlers-Danlos syndrome (EDS), endometriosis, eosinophilia-myalgia syndrome (EMS), erythromelalgia, fibromyalgia, gout, headaches, herniated disc, hydrocephalus, intercostal neuralgia, interstitial cystitis, irritable bowel syndrome (IBS), juvenile dermatositis (dermatomyositis), knee injury, leg pain, loin pain-haematuria syndrome, lupus, Lyme disease, medullary sponge kidney (MSK), meralgia paresthetica, mesothelioma, migraine, musculoskeletal pain, myofascial pain, myositis, neck pain, neuropathic pain, occipital neuralgia, osteoarthritis, Paget's disease, pain crisis in sickle cell disease; Parsonage-Turner syndrome, pelvic pain, periodontitis pain, peripheral neuropathy, phantom limb pain, pinched nerve, polycystic kidney disease, polymyalgia rheumatica, polymyositis, porphyria, post herniorrhaphy pain syndrome, post mastectomy pain, postoperative pain, pain syndrome, post stroke pain, post thoracotomy pain syndrome, postherpetic neuralgia (shingles), post-polio syndrome, primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, radiculopathy, raynaud's disease, rheumatoid arthritis (RA), sacroiliac joint dysfunction, sarcoidosis, Scheuermann's kyphosis disease, sciatica, scoliosis, shingles (herpes zoster), Sjögren's syndrome, spasmodic torticollis, sphincter of oddi dysfunction, spinal cerebellum ataxia (SCA ataxia), spinal cord injury, spinal stenosis, syringomyelia, Tarlov cysts, transverse myelitis, trigeminal neuralgia, neuropathic pain, ulcerative colitis, vascular pain and vulvodynia.

### Claim 86 (depends on 81)

The method of claim 81, wherein the MRGPRX2 dependent condition is a pseudo-allergic reaction.

### Claim 87 (depends on 86)

The method of claim 86, wherein the MRGPRX2 dependent condition is a pseudo-allergic reaction caused by a secretagogue, cationic peptidergic drug, anionic peptidergic drug, neutral peptidergic drug, non-steroidal antiinflammatory drugs, neuropeptides, antimicrobial peptides, opioids, neuromuscular blocking agents, antidepressant agents, antipsychotic agents, antihistamine agents, antineoplastic agents, fluoroquinolone and non-fluoroquinolone antibiotics and tyrosine-kinase inhibitors.

### Claim 88 (depends on 86)

The method of claim 86, wherein the MRGPRX2 dependent condition is a pseudo-allergic reaction caused by MCD peptide, substance P, VIP, PACAP, dynorphin, somatostatin, Compound 48/80, cortistatin-14, mastoparan, melittin, a cathelicidin peptide, ciprofloxacin, vancomycin, leuprolide, goserelin, histrelin, triptorelin, cetrorelix, ganirelix, degarelix, octreotide, lanreotide, pasireotide, sermorelin, tesamorelin, icatibant, glatiramer acetate, teriparatide, pramlintide, bleomycin, exenatide, glucagon, liraglutide, enfuvirtide, colistimethate, succinylcholine, tubocurarine, atracurium, mivacurium, or rocuronium.

### Claim 89 (depends on 81)

The method of claim 81, wherein the MRGPRX2 dependent condition is an autoimmune or inflammatory disorder.

### Claim 90 (depends on 89)

The method of claim 89, wherein the MRGPRX2 dependent condition is an autoimmune or inflammatory disorder selected from as chronic inflammation, mast cell activation syndrome, multiple sclerosis, Steven Johnson's syndrome, toxic epidermal necrolysis, appendicitis, bursitis, cutaneous lupus, colitis, cystitis, dermatitis, phlebitis, reflex sympathetic dystrophy/complex regional pain syndrome (RSD/CRPS), rhinitis, tendonitis, tonsillitis, acne vulgaris, sinusitis, rosacea, psoriasis, graft-versus-host disease, reactive airway disorder, asthma, airway infection, allergic rhinitis, autoinflammatory disease, celiac disease, chronic prostatitis, diverticulitis, glomerulonephritis, hidradenitis suppurativa, hypersensitivities, intestinal disorder, epithelial intestinal disorder, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, lupus erythematous, interstitial cystitis, otitis, pelvic inflammatory disease, endometrial pain, reperfusion injury, rheumatic fever, rheumatoid arthritis, sarcoidosis, transplant rejection, psoriasis, lung inflammation, chronic obstructive pulmonary disease, permanent sputum eosinophilia, eosinophilic leukemia, eosinophilic esophagitis, eosinophilic gastritis, eosinophilic duodenitis, eosinophilic gastroenteritis, mast cell gastrointestinal disease, hypereosinophilic syndrome, aspirin-exacerbated respiratory disease, nasal polyposis, chronic rhinosinusitis, antibody-dependent cell-mediated cytotoxicity, neurofibromatosis, schwannomatosis, tubulointerstitial nephritis, glomerulonephritis, diabetic nephropathy, allograft rejection, amyloidosis, renovascular ischemia, reflux nephropathy, polycystic kidney disease, liver fibrosis/cirrhosis, autoimmune liver disease, biliary atresia, acute and chronic hepatitis B and C virus, liver tumors and cancers, alcoholic liver disease, polycystic liver disease, liver cholangiocarcinoma, primary sclerosing cholangitis, primary biliary cholangitis, neuromyelitis optica spectrum disorder, cardiovascular disease, inflammation induced by bacterial or viral infection, inflammation associated with SARS-COV-2 infection or its variants or coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome, pneumonia, long/long-term/chronic COVID, postacute sequelae of COVID-19 (PASC), myalgic encephalomyelitis, chronic fatigue syndrome and vasculitis

### Claim 91 (depends on 81)

The method of claim 81, wherein the MRGPRX2 dependent condition is a cancer or tumor associated condition.

### Claim 92 (depends on 91)

The method of claim 91, wherein the MRGPRX2 dependent condition is a cancer or tumor associated condition selected from as adenoid cystic carcinoma, adrenal gland tumor, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, cholangiocarcinoma, Birt-Hogg-Dubé syndrome, bone cancer, brain stem glioma, brain tumor, breast cancer (inflammatory, metastatic, male), prostrate, basal cell, melanoma, colon, colorectal, bladder, kidney cancer, lacrimal gland cancer, laryngeal and hypopharyngeal cancer, lung cancer (non-small cell, small cell), leukemia (acute lymphoblastic, acute lymphocytic, acute myeloid, B cell prolymphocytic, chronic lymphocytic, chronic myeloid, chronic T cell lymphocytic, eosinophilic), liver cancer, Li-Fraumeni syndrome, lymphoma (Hodgkin and non-Hodgkin), lynch syndrome, mastocytosis, medulloblastoma, meningioma, mesothelioma, multiple endocrine neoplasia, multiple myeloma, MUTYH-associated polyposis, myelodysplastic syndrome, nasal cavity and paranasal sinus cancer, neuroblastoma, neuroendocrine tumors, neurofibromatosis, penile cancer, parathyroid cancer, ovarian fallopian tube and peritoneal cancer, osteosarcoma, pituitary gland tumor, pleuropulmonary blastoma, oral and oropharyngeal, thyroid, uterine, pancreatic, carney complex, brain and spinal cord cancer, cervical cancer, Cowden syndrome, craniopharyngioma, desmoid tumor, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor, germ cell tumor, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary, leiomyomatosis and renal cell cancer, hereditary pancreatitis, hereditary papillary renal carcinoma, hereditary mixed polyposis syndrome, HIV/AIDS related cancers, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Kaposi sarcoma, small bowel cancer, stomach cancer, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, vaginal cancer, culver cancer, Wermer's syndroeroderma pigmentosum.

### Claim 93 (depends on 80)

The method of claim 80, wherein the MRGPRX2 dependent condition is selected from abdominal aortic aneurysms, acute contact dermatitis, allergic rhinitis, amyotrophic lateral sclerosis, asthma, atopic dermatitis, autism, cancer, chronic inducible urticaria, chronic itch, chronic obstructive pulmonary disease, chronic spontaneous urticaria, cold urticaria, contact urticaria, coronary artery disease, cough, Crohn's disease, deep vein thrombosis, drug-induced anaphylactic reactions, endometriosis, fibromyalgia, geographic atrophy, idiopathic chronic cough, idiopathic pulmonary fibrosis, inflammatory pain, interstitial cystitis, irritable bowel syndrome, mast cell activation syndrome, mastocytosis, metabolic syndrome, migraine, multiple sclerosis, nasal polyps, neurodermatitis, neuropathic itch, neuropathic pain, obesity, oesophageal reflux, osteoarthritis, periodontitis, prurigo nodularis, pruritus, pseudo-anaphylaxis, psoriasis, rheumatoid arthritis, rosacea, seborrheic dermatitis, sickle cell disease, ulcerative colitis, and ulcers.

### Claim 94 (depends on 80)

The method of claim 80, wherein the MRGPRX2 dependent condition is selected from autoimmune diseases, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, graft-versus-host disease (GvHD), Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjögren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, ischemia reperfusion injury, stroke, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, scleroderma, and atopic dermatitis.

### Claim 95 (depends on 80)

The method of claim 80, wherein the MRGPRX2 dependent condition is selected from acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathies, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogan's syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathies, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly called Wegener's granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease, chronic, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, type I, II, & III autoimmune polyglandular syndromes, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm & testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenic purpura (TTP), tolosa-hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, and Wegener's granulomatosis (i.e., granulomatosis with polyangiitis (GPA)).
